Allergan, Inc. Quarterly Earnings Sneak Peek

S&P 500 (NYSE:SPY) component Allergan, Inc. (NYSE:AGN) will unveil its latest earnings on Wednesday, August 3, 2011. Allergan, Inc. is a global specialty health care company. It discovers, develops and commercializes innovative pharmaceuticals, biologics and medical devices, as well as over-the-counter products.

Allergan, Inc. Earnings Preview Cheat Sheet

Wall St. Earnings Expectations: The average estimate of analysts is for profit of 95 cents per share, a rise of 11.8% from the company’s actual earnings for the same quarter a year ago. During the past three months, the average estimate has moved up from 92 cents. For the year, analysts are projecting net income of $3.64 per share, a rise of 15.2% from last year.

Past Earnings Performance: The company topped estimates last quarter after missing forecasts the quarter prior. In the first quarter, it reported profit of 77 cents per share against a mean estimate of net income of 74 cents per share. In the fourth quarter of the last fiscal year, it missed forecasts by one cent.

Get more Earnings Cheat Sheets with our in depth coverage of earnings season >>

Wall St. Revenue Expectations: On average, analysts predict $1.34 billion in revenue this quarter, a rise of 7.2% from the year ago quarter. Analysts are forecasting total revenue of $5.31 billion for the year, a rise of 8.8% from last year’s revenue of $4.88 billion.

Analyst Ratings: 14 out of 22 analysts surveyed (63.6%) have a buy rating on Allergan.. This is below the mean analyst rating of 10 competitors, which average 72.5% buy ratings.

Key Stats:

Revenue has risen the past four quarters. Revenue increased 10.1% to $1.27 billion in first quarter. The figure rose 6.9% in the fourth quarter of the last fiscal year from the year earlier, climbed 5.9% in the third quarter of the last fiscal year from the year-ago quarter and 10.3% in the second quarter of the last fiscal year.

Competitors to Watch: Johnson & Johnson (NYSE:JNJ), Inspire Pharmaceuticals, Inc. (NASDAQ:ISPH), ISTA Pharmaceuticals, Inc. (NASDAQ:ISTA), Endo Pharmaceuticals (NASDAQ:ENDP), Medicis Pharmaceutical Corp. (NYSE:MRX), Akorn, Inc. (NASDAQ:AKRX), Novartis AG (NYSE:NVS), GlaxoSmithKline plc (NYSE:GSK), Merck & Co., Inc. (NYSE:MRK), and Hospira, Inc. (NYSE:HSP).

Stock Price Performance: During May 3, 2011 to July 28, 2011, the stock price had risen $2.82 (3.6%) from $78.93 to $81.75. The stock price saw one of its best stretches over the last year between March 31, 2011 and April 11, 2011 when shares rose for eight-straight days, rising 5.9% (+$4.19) over that span. It saw one of its worst periods between July 21, 2011 and July 27, 2011 when shares fell for five-straight days, falling 4.3% (-$3.61) over that span. Shares are up $13.17 (+19.2%) year to date.

(Source: Xignite Financials)

Get more Earnings Cheat Sheets with our in depth coverage of earnings season >>